Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Solute carrier family 4 member 9 (SLC4A9, also known as AE4) is a transmembrane protein primarily expressed in the kidney, especially in the basolateral membrane of β-intercalated cells. It functions chiefly as a cation-dependent chloride/bicarbonate exchanger, able to utilize sodium or potassium as the driving cation. This protein is involved in the regulation of intracellular and extracellular pH and plays essential roles in renal acid–base homeostasis and salivary gland secretion. Its dysfunction has been associated with renal tubular acidosis and other acid–base disorders. Structurally, SLC4A9 possesses a large intracellular N-terminal domain, multiple transmembrane domains, and displays complex alternative splicing, possibly generating isoforms with distinct transport characteristics[1][4][6][7].
Inhibition of chloride/bicarbonate exchange (potential drug mechanism); Modulation of sodium/bicarbonate cotransport (potential drug mechanism)[1][7]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Solute carrier family 4 member 9 (SLC4A9).